Creo Medical Group has announced its plans to find a new director to fill the role of chair to keep up with its increasing demand for technology. The endoscopic surgical device company reported revenue of 27.2 million pounds in the year 2022, and it has experienced growing demand for both its core technology and its range of endotherapy devices.
The company has been developing a comprehensive succession plan to ensure its board has the necessary skill mix across executive and non-executive directors. Creo seeks an experienced international medical technology executive as an additional independent non-executive director suitable to succeed Charles Spicer as Chair. According to the company, the changes will take effect by the 2024 shareholder annual meeting at the latest.
Creo has assured its shareholders that it has further developments in the pipeline, reduced operating costs and resolved the funding gap. As such, the board is committed to building a world-class medtech company that can deliver significant improvements for patients, thus leading to potential returns for investors.
As Creo Medical Group continues to experience unparalleled growth in demand for its technology, the company is streamlining its leadership to maintain its competitive edge and continue on its upward trajectory.
